FDA Calls Out Amgen Over Misleading Anemia Drug Claims

Law360, New York (November 22, 2013, 5:05 PM EST) -- Direct mailers from Amgen Inc. oversold the benefits of anemia drug Aranesp and omitted important information about its potential to cause heart attacks and strokes, according to a U.S. Food and Drug Administration letter released Friday.

In a so-called untitled letter, which addresses less serious violations than FDA warning letters, regulators accused California-based Amgen of presenting an incomplete portrait of risks in a four-page document.

While many of the drug’s possible side effects were listed, there was an absence of references to increased potential for deaths,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.